Skip to content
OpenCapital
Get started

ARS Pharmaceuticals, Inc. SPRY Q1 2026 earnings

Reported May 15, 2026 · Before market open

Revenue$22.7MBeat by $481.0KDiluted EPS-$0.61Miss by $0.08
Revenue estimate$22.2M
EPS estimate-$0.53

Next report

Aug 12, 2026 (in a month)
Revenue estimate$31.3M
EPS estimate-$0.48

Financials

Q1 2026

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Cash & equivalents$24.3M-39.0%
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$782.51M-35.4%
Enterprise value$854.71M-27.2%
P/S7.9×-4.6×

Profitability

See full
Operating margin-204.5%—
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Segments

By geography

See full
Non Us$2.5M—

Versus estimates

Revenue

Q1 2026$22.7MBeat by $481.0K
Q4 2025$28.1MBeat by $2.5MQ3 2025$32.5MBeat by $6.9MQ2 2025$15.7MMiss by $12.0MQ1 2025$8.0MMiss by $6.7MQ4 2024$86.6MBeat by $73.7M

Diluted EPS

Q1 2026-$0.61Miss by $0.08
Q4 2025-$0.42In lineQ3 2025-$0.52Miss by $0.07Q2 2025-$0.46Miss by $0.05Q1 2025-$0.35In lineQ4 2024$0.52Beat by $0.56

Ask the moment ARS Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ARS Pharmaceuticals, Inc. report Q1 2026 earnings?
ARS Pharmaceuticals, Inc. (SPRY) reported Q1 2026 earnings on May 15, 2026 before market open.
What were ARS Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
ARS Pharmaceuticals, Inc. reported revenue of $22.7M and diluted EPS of $-0.61 for Q1 2026.
Did ARS Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $22.2M by $481.0K. EPS missed the consensus estimate of $-0.53 by $0.08.
How did ARS Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 184.5% from $8.0M a year earlier and diluted EPS declined 74.3% from $-0.35.
Where can I find ARS Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-220671) and the 10-Q periodic report (0001193125-26-225142) directly on SEC EDGAR. The filing index links above go to sec.gov.